Invesco High Yield Equity Dividend Achievers ETF (NASDAQ: PEY)

最新ニュース Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:PEY)

Invesco High Yield Equity Dividend Achievers ETF

Utilities

Financial Services

Consumer Defensive

Communication Services

Industrials

Healthcare

Consumer Cyclical

Basic Materials

Energy

Technology

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq, Inc. includes common stocks in the underlying index that have a consistent record of dividend increases, principally on the basis of dividend yield and consistent growth in dividends.

Altria Group Inc

First Interstate Bancsystem Inc

Cogent Communications Fin

Universal Corp/va

Bristol-Myers Squibb Co.

Walgreens Boots Alliance Inc.

Truist Financial Corp Common Stock USD5.0

Keybank

Pfizer, Inc.

PARALLEL ENERGY TR by Parallel Energy Trust

PEYTO EXPL & DEV CORP by Peyto Exploration & Development Corp

Peyto Exploration & Development Corp

On Thursday, Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) reached an agreement for the early settlement of certain prepaid variable share forward transactions related to shares of Cencora, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COR#NYSE">COR</a>).
As part of the early settlement, Walgreens Boots will transfer approximately 6.1 million Cencora shares to the financial institutions and make a net cash payment of about $20 million.
Alongside this, the company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The company receives approximately&nbsp;$300 million&nbsp;from the early settlement and the concurrent sale of shares.
Following this settlement, WBA retains 12.6 million Cencora shares under remaining prepaid contracts, set to mature primarily in March, June, and September 2025, with the potential for additional cash proceeds.
The proceeds will primarily be used for debt reduction and general corporate purposes.&nbsp;&nbsp;The transactions were scheduled to mature in March and June 2026.
By settling early and executing a concurrent share sale, WBA is realizing the embedded cash value of the prepaid variable share forwards. With this settlement, Walgreens has lowered its stake in Cencora from 10% to 6%.
Notably, Walgreens has been cutting its stake in Concera for the last few years, decreasing the stake from 12% to 10% for around <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40119033/walgreens-boots-alliance-sells-shares-of-cencora-for-approximately-1-1-billion-of-proceeds" rel="noreferrer noopener">$1.1 billion in August 2024</a>.
Also, in May 2024,&nbsp;Walgreens reduced ownership of Cencora shares from 13% to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38975615/walgreens-boots-alliance-sells-shares-of-cencora-for-400-million-of-proceeds" rel="noreferrer noopener">12% for approximately $400 million</a>.
These transactions, along with other recent measures such as the dividend suspension, further strengthen WBA&#8217;s ability to address its upcoming debt maturities in fiscal 2026.
Last month, the company announced it is halting its quarterly dividend while the management team reviews and adjusts its capital allocation strategy to match the company&#8217;s <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43397182/whats-going-on-with-walgreens-shares-friday-2" rel="noreferrer noopener">broader long-term recovery efforts</a>.
Investors can gain exposure to the stock via Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEY#NASDAQ">PEY</a>) and Invesco S&amp;P 500 Equal Weight Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPS#NYSE">RSPS</a>).
Price Action: WBA shares are up 0.40% at $10.09 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/01/43390001/feds-favorite-inflation-gauge-rises-as-predicted-consumer-spending-jumps-at-fastest-pace-in-9-months" target="_blank" rel="noreferrer noopener">Fed&#8217;s Favorite Inflation Gauge Rises As Predicted, Consumer Spending Jumps At Fastest Pace In 9 Months</a></li>
</ul>
Image via Shutterstock.

Equities

Mid Cap

News

Movers

RSPS

Walgreens Cashes In: Slashes Cencora Stake Again In Debt-Fighting Move

With market pullbacks driven by factors like geopolitical tensions, central bank policies, and fluctuating jobless claims, many investors are left wondering where to allocate their funds. While the allure of stock picking, especially in trending areas like AI, Chinese stocks, or energy, can be strong, it doesn&#39;t suit every investor, particularly those looking for a more conservative, income-focused approach.
Investing in high-quality ETFs with an income component can offer a practical and reliable solution for long-term stability without constant portfolio monitoring. Even Warren Buffett, a staunch S&amp;P 500 index fund advocate, suggests that ETFs are the best bet for most people. As he put it, &quot;In my view, for most people, the best thing to do is own the S&amp;P 500 index fund.&quot;
With that in mind, let&#39;s explore three that offer the long-term growth and income potential conservative investors seek. Each provides broad market exposure with the added income benefit, making them solid choices for a buy-and-hold strategy.
<h2>The Vanguard S&amp;P 500 ETF</h2>
The Vanguard S&amp;P 500 ETF (ARCA:VOO) is one of the most popular and reliable options for U.S. investors seeking stable, long-term returns. It&#39;s a perfect fit for those who prefer a &quot;set it and forget it&quot; strategy, as the fund tracks the performance of the S&amp;P 500 Index, widely considered a vital benchmark of the U.S. stock market.
The ETF&#39;s top holdings are led by the Magnificent Seven, which includes heavyweights like Apple, NVIDIA, Microsoft, and Amazon, providing exposure to some of the most influential companies in the market.
With a substantial $524 billion in assets under management (AUM), VOO offers a modest dividend yield of 1.14% and boasts a very low expense ratio of just 0.03%, making it one of the most cost-effective ETFs available. Ratings covering nearly 60% of its portfolio give the ETF a Moderate Buy rating, with a consensus price target suggesting a potential upside of around 10%.
VOO has delivered strong returns, up nearly 19.5% year-to-date and 32% over the past year, reflecting its ability to weather market fluctuations. The fund also provides diversified exposure across critical sectors, with 31.5% in technology, 13.2% in financials, and 12% in health care, offering a balanced approach for long-term investors looking for growth and stability.
<h2>The Energy Select Sector SPDR Fund</h2>
The Energy Select Sector SPDR Fund&nbsp;has gained notable traction recently, driven by escalating tensions in the Middle East, which threaten global oil production.
This ETF offers a strong income component and has broken out of a prolonged pullback, showing signs of continued upward momentum. This could be a timely opportunity for long-term investors to gain exposure to the energy sector.
XLE aims to track the performance of the Energy Select Sector Index, which includes companies from industries such as oil, gas, consumable fuels, and energy equipment and services. With a robust dividend yield of 3.44%, a low expense ratio of 0.09%, and over $37 billion in assets under management (AUM), XLE provides a cost-effective way to invest in energy.
The fund consists of 25 major energy companies, including household names like Exxon Mobil, Marathon Petroleum, and Chevron. Analyst ratings covering nearly the entire portfolio suggest a Moderate Buy rating, with a consensus price target forecasting a potential 13% upside. This makes XLE a compelling choice for those seeking long-term growth alongside income.
<h2>The Invesco High Yield Equity Dividend Achievers</h2>
The Invesco High Yield Equity Dividend Achievers ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pey#NASDAQ">PEY</a>) is a solid choice for investors seeking a high-yield, income-focused ETF. It tracks the Mergent Dividend Achiever 50 Index, including 50 stocks chosen for their strong dividend yield and consistent growth.
The fund allocates at least 90% of its assets to dividend-paying stocks from various sectors, including consumer discretionary, staples, energy, financials, healthcare, and information technology.
Though PEY has posted modest year-to-date gains of 1.56%, it has risen over 10% in the last three months, signaling a significant shift in momentum. It is approaching a critical resistance level near $22, which could signal a breakout, especially if the Federal Reserve continues cutting interest rates. With lower rates, high-yield stocks like those in PEY may become more attractive, potentially driving further gains.
The ETF offers a substantial 4.7% dividend yield and a reasonable expense ratio of 0.52%. Analysts covering 96% of the portfolio predict a 7.28% upside, making PEY an appealing option for income-seeking investors. High yield and potential capital appreciation could provide strong compounded returns over the long term.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-powerful-etfs-for-income-seekers-looking-to-maximize-gains/">3 Powerful ETFs for Income Seekers Looking to Maximize Gains</a>&quot; first appeared on MarketBeat.

Large Cap

Sector ETFs

Dividends

Health Care

Price Target

Offerings

Federal Reserve

Markets

Analyst Ratings

Tech

Trading Ideas

ETFs

General

3 Powerful ETFs for Income Seekers Looking to Maximize Gains

Retail pharmacy giant&nbsp;Walgreens Boots Alliance Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is bolstering its specialty pharmacy services, aiming&nbsp;to enhance patient outcomes and value for stakeholders.
The company unveiled Walgreens Specialty Pharmacy, an encompassing initiative to cater to patients with complex, chronic conditions while fostering profitable partnerships.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37967312/walgreens-challenges-nearly-1b-arbitration-award-over-alleged-breach-of-covid-19-test-business-con" rel="noreferrer noopener">Walgreens Challenges Nearly $1B Arbitration Award Over Alleged Breach of COVID-19 Test Business&nbsp;Contract</a>
Walgreens Specialty Pharmacy introduces a comprehensive suite of services, including gene and cell therapy solutions, marking a significant advancement in the company&#8217;s healthcare offerings.
Anchored by an 18,000-square-foot Innovation Center in Pittsburgh, Pennsylvania, the initiative focuses on managing therapy complexities and ensuring patient success.
Under the expanded business, Walgreens will operate four central specialty pharmacies, each with national accreditations and expertise in dispensing intricate medications.
Additionally, the company&#8217;s expansive network comprises nearly 300 community-based specialty&nbsp;pharmacies,&nbsp;strategically positioned for swift medication access and tailored patient services.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/03/37981845/walgreens-boots-alliance-cuts-higher-end-of-2024-profit-outlook-takes-5-8b-impairment-charge-relate" rel="noreferrer noopener">Walgreens Boots Alliance Cuts Higher End Of 2024 Profit Outlook, Takes $5.8B Impairment Charge Related To VillageMD&nbsp;Business</a>
With over 1,500 specialty-trained pharmacists and 5,000 patient advocacy support members, Walgreens Specialty Pharmacy&nbsp;is primed&nbsp;to address the burgeoning demand for specialized care.
Specialty medications constitute a significant portion of the U.S. prescription drug market, driving the need for tailored solutions.
Walgreens Specialty Pharmacy aims to meet this demand by streamlining care coordination across stakeholders, thereby enhancing patient access and driving cost efficiencies.
Effective August 1, 2024, AllianceRx Walgreens Pharmacy will transition to Walgreens Specialty Pharmacy, offering enhanced resources and clinical support to patients.
Walgreens&nbsp;stock lost over 48% in the last 12 months. Investors can gain exposure to the stock via&nbsp;Invesco High Yield Equity Dividend Achievers ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEY#NASDAQ">PEY</a>) and&nbsp;Invesco Dow Jones Industrial Average Dividend ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DJD#NYSE">DJD</a>).
Price Action: WBA shares are trading higher by 0.79% at $17.94 in premarket at last check Thursday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Wikimedia Commons

Walgreens Expands Specialty Pharmacy Business To Include Gene and Cell Services: Details

Earnings

Pre-Market Outlook

CSTE

CTKB

CYCC

DAVE

DIBS

DNUT

DXYN

ENJY

ENVX

EVAX

EVGO

EVLV

FLNC

FORG

FOSL

FREY

FRPH

FVRR

GAIN

GECC

GEOS

GPRK

HLTH

HYPR

ICAD

INTA

INVZ

IREN

ISPO

ISSC

KRNT

LIVE

LKCO

LMDX

LTBR

LUCD

MBII

MCFT

METC

MINM

MRAM

NGMS

NOAH

NOMD

NSYS

OBLG

OLPX

ONDS

ONTX

OTRK

OWLT

PAAS

PAYS

PCOM

PDSB

PFGC

PHGE

PIRS

PLSE

PRGO

PRTH

PSFE

PSTL

PYPD

PowerShares Insured Municipal Bond Portfolio

REPX

RIVN

SCTL

SLVM

SMRT

SMTS

Earnings Scheduled For May 11, 2022

&nbsp;
<h3>Companies Reporting Before The Bell</h3>
&bull; REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million.
&bull; Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPR#NYSE">EXPR</a>) is projected to report quarterly loss at $0.02 per share on revenue of $591.95 million.
&bull; Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) is expected to report quarterly earnings at $0.69 per share on revenue of $2.24 billion.
&bull; PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) is expected to report earnings for its fourth quarter.
&bull; BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) is expected to report quarterly loss at $0.07 per share on revenue of $7.98 million.
&bull; Children&#39;s Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) is expected to report quarterly earnings at $2.85 per share on revenue of $537.73 million.
&bull; Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) is projected to report earnings for its fourth quarter.
&bull; Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $30.77 million.
&bull; Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is estimated to report quarterly earnings at $0.47 per share on revenue of $263.58 million.
&bull; Korn Ferry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFY#NYSE">KFY</a>) is estimated to report quarterly earnings at $1.48 per share on revenue of $651.06 million.
&bull; Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) is estimated to report earnings for its fourth quarter.
&bull; Lightbridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTBR#NASDAQ">LTBR</a>) is estimated to report earnings for its fourth quarter.
&bull; Oatly Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLY#NASDAQ">OTLY</a>) is likely to report quarterly loss at $0.09 per share on revenue of $174.22 million.
&bull; Diversey Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSEY#NASDAQ">DSEY</a>) is likely to report quarterly earnings at $0.13 per share on revenue of $677.05 million.
&bull; ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is estimated to report quarterly earnings at $13.20 per share on revenue of $3.34 billion.
&bull; Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $157.75 million.
&bull; Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $109.20 million.
&bull; United Natural Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) is projected to report quarterly earnings at $1.14 per share on revenue of $7.15 billion.
&bull; Scienjoy Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJ#NASDAQ">SJ</a>) is likely to report quarterly earnings at $0.30 per share on revenue of $495.30 million.
&bull; Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is likely to report quarterly earnings at $3.39 per share on revenue of $3.57 billion.
&bull; Amryt Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMYT#NASDAQ">AMYT</a>) is projected to report quarterly loss at $0.15 per share on revenue of $56.81 million.
&bull; PowerFleet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PWFL#NASDAQ">PWFL</a>) is likely to report quarterly loss at $0.09 per share on revenue of $31.63 million.
&bull; Overseas Shipholding Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSG#NYSE">OSG</a>) is estimated to report earnings for its fourth quarter.
&nbsp;
<h3>Companies Reporting After The Bell</h3>
&bull; Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $257.99 million.
&bull; Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) is expected to report quarterly loss at $0.28 per share on revenue of $105.16 million.
&bull; Costamare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMRE#NYSE">CMRE</a>) is expected to report quarterly earnings at $0.96 per share on revenue of $261.78 million.
&bull; Tiptree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIPT#NASDAQ">TIPT</a>) is projected to report earnings for its fourth quarter.
&bull; Earthstone Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTE#NYSE">ESTE</a>) is expected to report quarterly earnings at $0.35 per share on revenue of $116.63 million.
&bull; Stabilis Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNG#NASDAQ">SLNG</a>) is expected to report quarterly loss at $0.06 per share on revenue of $22.02 million.
&bull; Hamilton Beach Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) is likely to report quarterly earnings at $1.08 per share on revenue of $229.30 million.
&bull; SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) is likely to report earnings for its fourth quarter.
&bull; Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) is estimated to report quarterly loss at $0.49 per share on revenue of $2.98 million.
&bull; Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) is expected to report quarterly earnings at $0.39 per share on revenue of $91.56 million.
&bull; Lufax Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LU#NYSE">LU</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $2.39 billion.
&bull; MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $161.66 million.
&bull; Fiesta Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGI#NASDAQ">FRGI</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $88.48 million.
&bull; Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) is likely to report earnings for its fourth quarter.
&bull; SandRidge Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SD#NYSE">SD</a>) is likely to report earnings for its fourth quarter.
&bull; Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) is expected to report quarterly loss at $0.63 per share on revenue of $100.00 thousand.
&bull; Accel Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACEL#NYSE">ACEL</a>) is projected to report quarterly earnings at $0.19 per share on revenue of $191.59 million.
&bull; Mirum Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRM#NASDAQ">MIRM</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $62.65 million.
&bull; Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is projected to report earnings for its fourth quarter.
&bull; VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is estimated to report earnings for its fourth quarter.
&bull; Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $29.60 million.
&bull; CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) is estimated to report quarterly earnings at $0.09 per share on revenue of $85.33 million.
&bull; Sonder Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOND#NASDAQ">SOND</a>) is projected to report quarterly loss at $0.25 per share on revenue of $68.19 million.
&bull; Spire Globall (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $13.17 million.
&bull; Safeguard Scientifics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFE#NYSE">SFE</a>) is likely to report earnings for its fourth quarter.
&bull; Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is estimated to report quarterly loss at $0.25 per share on revenue of $34.00 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $27.62 million.
&bull; Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) is expected to report quarterly loss at $0.07 per share on revenue of $137.74 million.
&bull; Natura &amp;Co Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTCO#NYSE">NTCO</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $2.31 billion.
&bull; Trean Insurance Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIG#NASDAQ">TIG</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $134.49 million.
&bull; Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is expected to report earnings for its fourth quarter.
&bull; Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) is expected to report quarterly loss at $0.06 per share on revenue of $3.53 million.
&bull; KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $2.55 billion.
&bull; Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is likely to report earnings for its fourth quarter.
&bull; Stepan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCL#NYSE">SCL</a>) is likely to report quarterly loss at $0.05 per share on revenue of $250.67 million.
&bull; NeoGames (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGMS#NASDAQ">NGMS</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $20.65 million.
&bull; Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is projected to report quarterly earnings at $1.10 per share on revenue of $413.21 million.
&bull; ETF Series Solutions Blue Horizon BNE ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNE#NYSE">BNE</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $36.30 million.
&bull; Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is expected to report quarterly loss at $0.22 per share on revenue of $10.18 million.
&bull; VSE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEC#NASDAQ">VSEC</a>) is expected to report quarterly earnings at $0.78 per share on revenue of $203.71 million.
&bull; Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEY#NASDAQ">PEY</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $158.88 million.
&bull; Points.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCOM#NASDAQ">PCOM</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $106.62 million.
&bull; Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $10.10 million.
&bull; BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report earnings for its fourth quarter.
&bull; Innovate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VATE#NYSE">VATE</a>) is likely to report earnings for its fourth quarter.
&bull; ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is projected to report quarterly loss at $0.10 per share on revenue of $18.66 million.
&bull; Allied Motion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOT#NASDAQ">AMOT</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $96.42 million.
&bull; AgroFresh Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGFS#NASDAQ">AGFS</a>) is expected to report quarterly loss at $0.03 per share on revenue of $53.29 million.
&bull; Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) is estimated to report earnings for its fourth quarter.
&bull; CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $410.91 million.
&bull; Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is estimated to report earnings for its fourth quarter.
&bull; Red Violet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDVT#NASDAQ">RDVT</a>) is estimated to report earnings for its fourth quarter.
&bull; Central Puerto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEPU#NYSE">CEPU</a>) is estimated to report earnings for its fourth quarter.
&bull; Granite Real Estate Inc. Stapled Units, each consisting of one unit of Granite Real Estate Trust and one common share of Granite REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRP#NYSE">GRP</a>) is estimated to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

Comments

Invesco High Yield Equity Dividend Achievers ETF

ニュース

最新ニュース Invesco High Yield Equity Dividend Achievers ETF (NASDAQ:PEY)

ニュース

パートナーシップ

ベンジンガ・グローバル